No Data
Bide Pharmaceutical (688073.SH): Plans to launch the 2024 restricted Stocks incentive plan.
On December 20, Gelonghui reported that Bida Pharmaceuticals (688073.SH) announced its 2024 restricted stock incentive plan, which plans to grant a total of 2.554024 million shares of restricted stock to incentive targets, accounting for approximately 2.81% of the company's total share capital of 90.882948 million shares as of the date of the announcement of this incentive plan draft. A total of 65 individuals are involved in the initial grant of this incentive plan, with the granting price for the restricted stock set at 24.96 yuan per share, meaning that once the granting conditions and vesting conditions are met, the incentive targets can purchase company stock at the price of 24.96 yuan per share.
These 4 Measures Indicate That Bide Pharmatech (SHSE:688073) Is Using Debt Reasonably Well
Bidang Pharmaceutical (688073.SH): The actual controller Dai Lan has proposed that the company repurchase shares again.
Gelonghui, on November 25, reported that Bid Pharmaceutical (688073.SH) announced that the company's board of directors received a letter from Mrs. Dai Lan, the actual controller, chairman, and general manager of the company, on November 24, 2024, proposing that Shanghai Bid Pharmaceutical Technology Co., Ltd. buy back a portion of its issued ordinary shares (A-shares) through the centralized bidding trading method in the Shanghai Stock Exchange trading system. The repurchased shares will be used for the company's stock-based incentive plan or employee stock ownership plan, or to cancel and reduce the company's registered capital. The total amount of funds for the buyback will not be less than 50 million yuan.
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
